Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · TG Therapeutics (TGTX)

TG Therapeutics Q4 revenue rises to $192.6M; 2026 revenue target $875-900M

Mixed Impact 4 of 5 earnings Written later

TG Therapeutics reported fourth-quarter and full-year 2025 results, with total revenue of $192.6 million for the quarter and $616.3 million for the year, driven by BRIUMVI sales. Fourth-quarter net income was $23.0 million, slightly below the prior-year quarter, while full-year net income of $447.2 million includes a non-recurring income tax benefit of approximately $339.8 million. The company set a 2026 target of approximately $875-$900 million in total global revenue.

Key points

  • Q4 2025 total revenue was $192.6 million, versus $108.2 million in Q4 2024; full-year 2025 total revenue was $616.3 million, versus $329.0 million in 2024.
  • Q4 2025 net income was $23.0 million, versus $23.3 million in Q4 2024; full-year 2025 net income of $447.2 million includes a tax benefit of approximately $339.8 million.
  • 2026 targets: total global revenue of approximately $875-$900 million and BRIUMVI U.S. net product revenue of approximately $825-$850 million.
  • Cash, cash equivalents and investment securities were $199.5 million as of December 31, 2025; a new share repurchase program of up to $100 million was announced.

The filing

CompanyTG Therapeutics (TGTX)
Form8-K, current report
Filed with the SECFeb 26, 2026, 7:08 AM ET
Accession number0001437749-26-005733

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.